Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 201300643 | Other Grant/Funding Number | Alberta Innovates - Health Solutions |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Alberta Innovates Health Solutions | OTHER |
| University of Waterloo | OTHER |
| University of Mississippi Medical Center | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Background: Despite evidence of benefit for pharmacist involvement in chronic disease management, the provision of these services in community pharmacy has been suboptimal. The Promoting Action on Research Implementation in Health Services (PARiHS) framework suggests that for knowledge translation to be effective, there must be evidence of benefit, a context conducive to implementation, and facilitation to support uptake. We hypothesize that while the evidence and context components of this framework are satisfied, that uptake into practice has been insufficient because of a lack of facilitation. This protocol describes the rationale and methods of a feasibility study to test a facilitated pharmacy practice intervention based on the PARiHS framework, to assist community pharmacists in increasing the number of formal and documented medication management services completed for patients with diabetes, dyslipidemia, and hypertension.
Methods: A cluster-randomized before-after design will compare ten pharmacies from within a single organization, with the unit of randomization being the pharmacy. Pharmacies will be randomized to facilitated intervention based on the PARiHS framework or usual practice. The Alberta Context Tool will be used to establish the context of practice in each pharmacy. Pharmacies randomized to the intervention will receive task-focused facilitation from an external facilitator, with the goal of developing alternative team processes to allow the greater provision of medication management services for patients with diabetes, hypertension, and dyslipidemia. The primary outcome will be a process evaluation of the needs of community pharmacies to provide more clinical services, the acceptability and uptake of modifications made, and the willingness of pharmacies to participate. Secondary outcomes will include the change in the number of formal and documented medication management services in the aforementioned chronic conditions provided 6 months before, versus after, the intervention between the two groups, and identification of feasible quantitative outcomes for evaluating the effect of the intervention on patient care outcomes.
Results: To date, the study has identified and enrolled the ten pharmacies required and initiated the intervention process.
Conclusion: This study will be the first to examine the role of facilitation in pharmacy practice, with the goal of scalable and sustainable practice change.
Please see the following publication for a detailed description of the work:
Pilot and Feasibility Studies 01/2015; 1(2). DOI: 10.1186/2055-5784-1-2
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Task-focused facilitation | Experimental | An external, task-focused facilitation, informed by an evaluation of contextual factors using the Alberta Context Tool (ACT), will be applied to train community pharmacies to develop alternative team processes that enable a greater number of medication management services to be provided to patients with diabetes, hypertension, and/or dyslipidemia. |
|
| Control | No Intervention | These sites will continue practice as usual, with no contact from study staff. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Task-focused facilitation | Behavioral | An external, task-focused facilitation, informed by an evaluation of contextual factors using the Alberta Context Tool (ACT), will be applied to train community pharmacies to develop alternative team processes that enable a greater number of medication management services to be provided to patients with diabetes, hypertension, and/or dyslipidemia. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Service Counts From Baseline to End of Intervention Period | Difference in the number of billable services (influenza vaccinations, Comprehensive Annual Care Plans and follow-ups, and Standard Medication Management Assessments and follow-ups) between the intervention period and the 6-months prior to intervention (baseline) | 6 month intervention period vs. 6 month baseline prior to intervention |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ross T Tsuyuki, PharmD, MSc | University of Alberta | Principal Investigator |
| Meagen M Rosenthal, BA, MA, PhD | University of Alberta | Study Director |
| Sherilyn KD Houle, BSP, PhD | University of Waterloo | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| EPICORE Centre, University of Alberta | Edmonton | Alberta | T6G 2M8 | Canada |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 27965782 | Derived | Rosenthal MM, Tsuyuki RT, Houle SK. A cluster-randomized controlled knowledge translation feasibility study in Alberta community pharmacies using the PARiHS framework: study protocol. Pilot Feasibility Stud. 2015 Jan 12;1:2. doi: 10.1186/2055-5784-1-2. eCollection 2015. | |
| 27017157 | Derived | Houle SK, Charrois TL, Faruquee CF, Tsuyuki RT, Rosenthal MM. A randomized controlled study of practice facilitation to improve the provision of medication management services in Alberta community pharmacies. Res Social Adm Pharm. 2017 Mar-Apr;13(2):339-348. doi: 10.1016/j.sapharm.2016.02.013. Epub 2016 Mar 8. |
| Label | URL |
|---|---|
| Study protocol | View source |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Task-focused Facilitation | An external, task-focused facilitation, informed by an evaluation of contextual factors using the Alberta Context Tool (ACT), will be applied to train community pharmacies to develop alternative team processes that enable a greater number of medication management services to be provided to patients with diabetes, hypertension, and/or dyslipidemia. Task-focused facilitation: An external, task-focused facilitation, informed by an evaluation of contextual factors using the Alberta Context Tool (ACT), will be applied to train community pharmacies to develop alternative team processes that enable a greater number of medication management services to be provided to patients with diabetes, hypertension, and/or dyslipidemia. |
| FG001 | Control | These sites will continue practice as usual, with no contact from study staff. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Unit of analysis pharmacies
| ID | Title | Description |
|---|---|---|
| BG000 | Task-focused Facilitation | An external, task-focused facilitation, informed by an evaluation of contextual factors using the Alberta Context Tool (ACT), will be applied to train community pharmacies to develop alternative team processes that enable a greater number of medication management services to be provided to patients with diabetes, hypertension, and/or dyslipidemia. Task-focused facilitation: An external, task-focused facilitation, informed by an evaluation of contextual factors using the Alberta Context Tool (ACT), will be applied to train community pharmacies to develop alternative team processes that enable a greater number of medication management services to be provided to patients with diabetes, hypertension, and/or dyslipidemia. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Customized | Number |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change in Service Counts From Baseline to End of Intervention Period | Difference in the number of billable services (influenza vaccinations, Comprehensive Annual Care Plans and follow-ups, and Standard Medication Management Assessments and follow-ups) between the intervention period and the 6-months prior to intervention (baseline) | Units of measure were community pharmacies | Posted | Count of Units | Billable pharmacy services | 6 month intervention period vs. 6 month baseline prior to intervention | Billable pharmacy services | Billable pharmacy services |
|
Not provided
Adverse events were not collected.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Task-focused Facilitation | An external, task-focused facilitation, informed by an evaluation of contextual factors using the Alberta Context Tool (ACT), will be applied to train community pharmacies to develop alternative team processes that enable a greater number of medication management services to be provided to patients with diabetes, hypertension, and/or dyslipidemia. Task-focused facilitation: An external, task-focused facilitation, informed by an evaluation of contextual factors using the Alberta Context Tool (ACT), will be applied to train community pharmacies to develop alternative team processes that enable a greater number of medication management services to be provided to patients with diabetes, hypertension, and/or dyslipidemia. |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Meagen Rosenthal | University of Mississippi | 662-915-2475 | mmrosent@olemiss.edu |
Not provided
| ID | Term |
|---|---|
| D002908 | Chronic Disease |
| D006973 | Hypertension |
| D003920 | Diabetes Mellitus |
| D050171 | Dyslipidemias |
| ID | Term |
|---|---|
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D014652 | Vascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| BG001 | Control | These sites will continue practice as usual, with no contact from study staff. |
| BG002 | Total | Total of all reporting groups |
| Pharmacies |
|
| Age data not collected |
| Pharmacies |
|
| Sex/Gender, Customized | Number | Pharmacies | Pharmacies |
|
| Alberta context tool, semi-structured interviews, medication management counts, close out interviews | The Alberta Context Tool is designed to obtain a measure of the organizational culture of a clinical setting. The scale is measured on a series of 5-point Likert scales from strongly disagree to strongly agree or never to almost always. Each of the five items is assigned a number from 1 (strongly disagree/never) to 5 (strongly agree/almost always). Composite scores (mean scores taken of responses to each item) are calculate for each of the sub-scales and combined for a total score. The higher the score the more a site demonstrates the sub-scale characteristic. | Mean | Full Range | units on a scale | Pharmacies |
|
| OG001 | Control | These sites will continue practice as usual, with no contact from study staff. |
|
|
| 0 |
| 0 |
| 0 |
| 0 |
| EG001 | Control | These sites will continue practice as usual, with no contact from study staff. | 0 | 0 | 0 | 0 |
Not provided
Not provided
| D002318 | Cardiovascular Diseases |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
| D052439 | Lipid Metabolism Disorders |